A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers

Slides:

Advertisements

Similar presentations

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Advertisements

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

ALK FISH and IHC: You Cannot Have One without the Other

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer Ramón Rami-Porta, MD, FETCS,

Electronic Updates for JTO Readers

Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study Eric.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Feiran Lou, MD, MS, Camelia S. Sima, MD, MS, Prasad S

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Early Stage Lung Cancer: Progress in the Last 40 Years

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Mitotic Inhibitors Journal of Thoracic Oncology

P3-255: Tumor size as a prognostic factor for the survival of surgically treated stage Ia non-small cell carcinoma Gustavo A. Lyons, Silvia Quadrelli,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Phase I Study of Lenalidomide in Solid Tumors

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

IASLC 6th Latin American Conference on Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Who should decide margin length in pulmonary excision of lung cancer?

Mark I. Block, MD The Annals of Thoracic Surgery

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Nael Martini, MDa, Valerie W. Rusch, MDa, Manjit S. Bains, MDa, Mark G

Mark A. Socinski, MD Journal of Thoracic Oncology

Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non–Small-Cell Lung Cancers Alexander Drilon, MD, Hirofumi Sugita, PhD, Camelia S. Sima, MD, Marjorie Zauderer, MD, Charles M. Rudin, MD, PhD, Mark G. Kris, MD, Valerie W. Rusch, MD, Christopher G. Azzoli, MD Journal of Thoracic Oncology Volume 9, Issue 9, Pages 1272-1277 (September 2014) DOI: 10.1097/JTO.0000000000000256 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Frequency of promoter gene methylation in resected stage I to IIIA NSCLCs. The percentage of tumors with methylated promoter regions of 10 tumor suppressor genes is depicted. Genes whose promoter regions were found to be methylated in at least 50% of samples tested include CDH13 (87%), WIF1 (64%), DAPK (62%), APC (57%), and RASSF1A (50%). ADAMTS8 (36%), CDKN2A (31%), MGMT (8%), and GSTP1 (5%) were less often methylated. SOCS3 was not found to be methylated in any samples. Journal of Thoracic Oncology 2014 9, 1272-1277DOI: (10.1097/JTO.0000000000000256) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Correlation between WIF1 and GSTP1 promoter methylation and pathologic stage. The percentage of tumors with methylated WIF1 and GSTP1 promoter regions is shown in relation to pathologic T and N stage, respectively. Increasing WIF1 promoter methylation was associated with increasing pathologic T stage (p = 0.01). Increasing GSTP1 methylation correlated with increasing pathologic N stage (p = 0.03). Journal of Thoracic Oncology 2014 9, 1272-1277DOI: (10.1097/JTO.0000000000000256) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions